Effect of Ketoconazole On Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

被引：1
|
作者：
Cotreau, M. [1 ]
Siebers, N.
Massmanian, L. [1 ]
Strahs, A. [1 ]
Vargo, D. [1 ]
机构：
[1] AVEO Oncol, Clin Pharmacol, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72392-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
595
引用
下载
收藏
页码：182 / 183
页数：2
相关论文
共 50 条
  • [41] Novel inhibitor for fibroblast growth factor receptor tyrosine kinase
    Kammasuda, Naparat
    Boonyarat, Chantana
    Tsunoda, Satoshi
    Sakurai, Hiroaki
    Saiki, Ikuo
    Grierson, David S.
    Vajragupta, Opa
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (17) : 4812 - 4818
  • [42] ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
    Rich, JN
    Sathornsumetee, S
    Keir, ST
    Kieran, MW
    Laforme, A
    Kaipainen, A
    McLendon, RE
    Graner, MW
    Rasheed, BKA
    Wang, L
    Reardon, DA
    Ryan, AJ
    Wheeler, C
    Dimery, I
    Bigner, DD
    Friedman, HS
    CLINICAL CANCER RESEARCH, 2005, 11 (22) : 8145 - 8157
  • [43] Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor
    Gallicchio, M
    Mitola, S
    Valdembri, D
    Fantozzi, R
    Varnum, B
    Avanzi, GC
    Bussolino, F
    BLOOD, 2005, 105 (05) : 1970 - 1976
  • [44] A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the anti proliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines
    Kim, Elizabeth M. H.
    Lobocki, Catherine
    Dubay, Linda
    Mittal, Vijay K.
    AMERICAN JOURNAL OF SURGERY, 2009, 197 (03): : 331 - 335
  • [45] Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
    Wulkersdorfer, Beatrix
    Zeitlinger, Markus
    Schmid, Monika
    CLINICAL PHARMACOKINETICS, 2016, 55 (01) : 47 - 77
  • [46] Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
    Beatrix Wulkersdorfer
    Markus Zeitlinger
    Monika Schmid
    Clinical Pharmacokinetics, 2016, 55 : 47 - 77
  • [47] A phase Ib study of escalating doses of Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitor Tivozanib and FOLFOX6 in patients with advanced gastrointestinal (GI) tumors
    Eskens, F.
    Oldenhuis, C.
    Bhargava, P.
    Loos, W.
    Esteves, B.
    van Doorn, L.
    Cotreau, M.
    Dillon, R.
    Gietema, J.
    de Vries, E.
    EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [48] Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals
    Ling, Jie
    Fettner, Scott
    Lum, Bert L.
    Riek, Myriam
    Rakhit, Ashok
    ANTI-CANCER DRUGS, 2008, 19 (02) : 209 - 216
  • [49] AEE788 IS A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR WITH A POTENT IN VITRO ACTIVITY IN ACUTE MYELOID LEUKEMIA
    Barbarroja, N.
    Torres, L. -A.
    Carretero, R. M.
    Luque, M. J.
    Rodriguez-Ariza, A.
    Velasco, F.
    Lopez-Pedrera, Ch.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 539 - 539
  • [50] The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis
    Heckman, Caroline A.
    Holopainen, Tanja
    Wirzenius, Maria
    Keskitalo, Salla
    Jeltsch, Michael
    Yla-Herttuala, Seppo
    Wedge, Stephen R.
    Jurgensmeier, Juliane M.
    Alitalo, Kari
    CANCER RESEARCH, 2008, 68 (12) : 4754 - 4762
12345